Patrick Soon-Shiong - 31 Mar 2026 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Reporting relationship
Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner
Issuer ticker
IBRX
Reported as of
31 Mar 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
02 Apr 2026, 20:08:43 UTC
Prior SEC filing
24 Feb 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Patrick Soon-Shiong, /s/ Charles Kenworthy, Manager of MP 13 Ventures, on behalf of itself and as General Partner of Cambridge Equities, and /s/ Charles Kenworthy, Manager of California Capital Equity and Manager...
Open signature details
/s/ Patrick Soon-Shiong, /s/ Charles Kenworthy, Manager of MP 13 Ventures, on behalf of itself and as General Partner of Cambridge Equities, and /s/ Charles Kenworthy, Manager of California Capital Equity and Manager of Nant Capital

Key filing fact

Patrick Soon-Shiong filed Form 4 for ImmunityBio, Inc. (IBRX) on 02 Apr 2026.

Key facts

  • This page summarizes Patrick Soon-Shiong's Form 4 filing for ImmunityBio, Inc. (IBRX).
  • 2 reported transactions and 5 derivative rows are listed below.
  • Accepted by SEC: 02 Apr 2026, 20:08.

Change

  • Previous filing in this sequence was filed on 24 Feb 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (5)

CIK 0001189020 Primary reporting owner

SOON-SHIONG PATRICK

Relationship
Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner
Address
C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO
Signature
/s/ Patrick Soon-Shiong, /s/ Charles Kenworthy, Manager of MP 13 Ventures, on behalf of itself and as General Partner of Cambridge Equities, and /s/ Charles Kenworthy, Manager of California Capital Equity and Manager of Nant Capital
Signature date
02 Apr 2026
CIK 0001517764

CALIFORNIA CAPITAL EQUITY, LLC

Relationship
10%+ Owner
Address
450 DULEY ROAD, EL SEGUNDO
Signature
/s/ Patrick Soon-Shiong, /s/ Charles Kenworthy, Manager of MP 13 Ventures, on behalf of itself and as General Partner of Cambridge Equities, and /s/ Charles Kenworthy, Manager of California Capital Equity and Manager of Nant Capital
Signature date
02 Apr 2026
CIK 0001629222

Cambridge Equities, LP

Relationship
10%+ Owner
Address
450 DULEY ROAD, EL SEGUNDO
Signature
/s/ Patrick Soon-Shiong, /s/ Charles Kenworthy, Manager of MP 13 Ventures, on behalf of itself and as General Partner of Cambridge Equities, and /s/ Charles Kenworthy, Manager of California Capital Equity and Manager of Nant Capital
Signature date
02 Apr 2026
CIK 0001629186

MP 13 Ventures, LLC

Relationship
10%+ Owner
Address
450 DULEY ROAD, EL SEGUNDO
Signature
/s/ Patrick Soon-Shiong, /s/ Charles Kenworthy, Manager of MP 13 Ventures, on behalf of itself and as General Partner of Cambridge Equities, and /s/ Charles Kenworthy, Manager of California Capital Equity and Manager of Nant Capital
Signature date
02 Apr 2026
CIK 0001675758

Nant Capital, LLC

Relationship
10%+ Owner
Address
450 DULEY ROAD, EL SEGUNDO
Signature
/s/ Patrick Soon-Shiong, /s/ Charles Kenworthy, Manager of MP 13 Ventures, on behalf of itself and as General Partner of Cambridge Equities, and /s/ Charles Kenworthy, Manager of California Capital Equity and Manager of Nant Capital
Signature date
02 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IBRX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+4,606,596
Change %
+1.9%
Price
$5.43*
Shares after
251,018,873
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F1
IBRX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+4,606,596
Change %
+1.9%
Price
$5.43*
Shares after
251,018,873
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F1
IBRX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+4,606,596
Change %
+1.9%
Price
$5.43*
Shares after
251,018,873
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F1
IBRX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+4,606,596
Change %
+1.9%
Price
$5.43*
Shares after
251,018,873
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F1
IBRX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+4,606,596
Change %
+1.9%
Price
$5.43*
Shares after
251,018,873
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F1
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
29,757,911
Date
31 Mar 2026
Ownership
Direct
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
29,757,911
Date
31 Mar 2026
Ownership
Direct
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
29,757,911
Date
31 Mar 2026
Ownership
Direct
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
29,757,911
Date
31 Mar 2026
Ownership
Direct
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
29,757,911
Date
31 Mar 2026
Ownership
Direct
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
261,705,814
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F2
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
261,705,814
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F2
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
261,705,814
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F2
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
261,705,814
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F2
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
261,705,814
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F2
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
8,383,414
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F3
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
8,383,414
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F3
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
8,383,414
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F3
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
8,383,414
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F3
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
8,383,414
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F3
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
7,976,159
Date
31 Mar 2026
Ownership
See footnte
Footnotes
F4
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
7,976,159
Date
31 Mar 2026
Ownership
See footnte
Footnotes
F4
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
7,976,159
Date
31 Mar 2026
Ownership
See footnte
Footnotes
F4
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
7,976,159
Date
31 Mar 2026
Ownership
See footnte
Footnotes
F4
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
7,976,159
Date
31 Mar 2026
Ownership
See footnte
Footnotes
F4
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
5,618,326
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F5
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
5,618,326
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F5
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
5,618,326
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F5
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
5,618,326
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F5
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
5,618,326
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F5
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
9,986,920
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F6
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
9,986,920
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F6
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
9,986,920
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F6
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
9,986,920
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F6
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
9,986,920
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F6
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
47,557,934
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F7
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
47,557,934
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F7
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
47,557,934
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F7
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
47,557,934
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F7
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
47,557,934
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F7
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
32,606,985
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F8
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
32,606,985
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F8
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
32,606,985
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F8
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
32,606,985
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F8
IBRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
32,606,985
Date
31 Mar 2026
Ownership
See footnote
Footnotes
F8

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IBRX transaction Derivative

Second Amended and Restated Convertible Promissory Note

Conversion of derivative security

Transaction value
Shares
Change %
Price
Shares after
$480,000,000
Date
31 Mar 2026
Ownership
See footnote
Underlying class
Common Stock
Underlying amount
Exercise price
$5.43
Footnotes
F1, F9
IBRX transaction Derivative

Second Amended and Restated Convertible Promissory Note

Conversion of derivative security

Transaction value
Shares
Change %
Price
Shares after
$480,000,000
Date
31 Mar 2026
Ownership
See footnote
Underlying class
Common Stock
Underlying amount
Exercise price
$5.43
Footnotes
F1, F9
IBRX transaction Derivative

Second Amended and Restated Convertible Promissory Note

Conversion of derivative security

Transaction value
Shares
Change %
Price
Shares after
$480,000,000
Date
31 Mar 2026
Ownership
See footnote
Underlying class
Common Stock
Underlying amount
Exercise price
$5.43
Footnotes
F1, F9
IBRX transaction Derivative

Second Amended and Restated Convertible Promissory Note

Conversion of derivative security

Transaction value
Shares
Change %
Price
Shares after
$480,000,000
Date
31 Mar 2026
Ownership
See footnote
Underlying class
Common Stock
Underlying amount
Exercise price
$5.43
Footnotes
F1, F9
IBRX transaction Derivative

Second Amended and Restated Convertible Promissory Note

Conversion of derivative security

Transaction value
Shares
Change %
Price
Shares after
$480,000,000
Date
31 Mar 2026
Ownership
See footnote
Underlying class
Common Stock
Underlying amount
Exercise price
$5.43
Footnotes
F1, F9
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 9 footnotes

Footnote F1

Shares held by Nant Capital, LLC, an investment vehicle of the Reporting Person.

Footnote F2

Shares held by Cambridge Equities, LP ("Cambridge Equities"). MP 13 Ventures, LLC ("MP 13 Ventures") is the general partner of Cambridge Equities and may be deemed to have beneficial ownership of the shares held by Cambridge Equities. The Reporting Person is the sole member of MP 13 Ventures and has voting and dispositive power over the shares held by Cambridge Equities.

Footnote F3

Shares held by NantBio, Inc. ("NantBio"). NantWorks, LLC ("NantWorks") is the majority stockholder and an affiliate of NantBio and may be deemed to have beneficial ownership of the shares held by NantBio. The Reporting Person is the chief executive officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the shares held by NantBio.

Footnote F4

Shares held by California Capital Equity, LLC ("CalCap"). The Reporting Person owns all of the equity interests of CalCap and has voting and dispositive power over the shares held by CalCap.

Footnote F5

Shares held by the Chan Soon-Shiong Family Foundation, an exempt corporation organized under the laws of the State of Delaware (the "Foundation"). The Foundation has the sole power to vote and direct the disposition of all shares directly owned by the Foundation, except to the extent it may be deemed to share such power with the Reporting Person by virtue of the Reporting Person's control over the Foundation. The Reporting Person serves as Chairman of the Foundation.

Footnote F6

Shares held by NantWorks. CalCap directly owns all of the equity interests of NantWorks and may be deemed to have beneficial ownership of the securities held by NantWorks. The Reporting Person directly owns all of the equity interests of CalCap and may be deemed to have voting and dispositive power over the securities held by NantWorks.

Footnote F7

Shares held by NantMobile, LLC ("NantMobile"). NantWorks is the majority stockholder and an affiliate of NantMobile and may be deemed to have beneficial ownership of the securities held by NantMobile. The Reporting Person is the Chief Executive Officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the securities held by NantMobile.

Footnote F8

Shares held by NantCancerStemCell, LLC ("NantCancerStemCell"). NantBio is the majority stockholder and an affiliate of NantCancerStemCell and may be deemed to have beneficial ownership of the securities held by NantCancerStemCell. NantWorks is the majority stockholder and an affiliate of NantBio and may be deemed to have beneficial ownership of the securities held by NantBio and its affiliates. The Reporting Person is the Chief Executive Officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the securities held by NantBio and its affiliates.

Footnote F9

Nant Capital has the right at any time after December 10, 2024 and on or before December 31, 2027 to convert all or a portion of the outstanding principal amount of this Second Amended and Restated Promissory Note, as amended January 23, 2026, into fully paid and nonassessable shares of the Issuer's common stock at a price per share equal to $5.427. On March 31, 2026, Nant Capital delivered notice to the Issuer electing to convert outstanding principal in the amount of $25,000,000 into 4,606,596 shares of the Issuer's common stock.

SEC remarks

Founder, Executive Chairman, Global Chief Scientific and Medical Officer

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .